COMBINATION ANTIHYPERTENSIVE THERAPY FOR MILD-TO-MODERATE ARTERIAL HYPERTENSION AND CONCOMITANT CORONARY HEART DISEASE
- Authors: Cheremushkin S.1, Kucheryavyi Y.1, Oganesyan T.1
-
Affiliations:
- N.A. Semashko Central Clinical Hospital Two, ОАО “RZhD”
- Issue: Vol 23, No 3 (2012)
- Pages: 76
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115379
- ID: 115379
Cite item
Abstract
The paper considers problems in the correction of arterial hypertension (AH) with nebivolol in patients with concomitant coronary heart disease (CHD). It gives the data of a prospective comparative study of the efficiency and safety (evaluation of clinical equivalence) of 2 combination therapy regimens using the generic Nebivator (INN Nebivolol; АТС code C07AB12) and the original drug Nebilet in patients with mild-to-moderate AH with concomitant CHD.
Full Text
About the authors
S. Cheremushkin
N.A. Semashko Central Clinical Hospital Two, ОАО “RZhD”
Email: svch555362@yandex.ru
Yu. Kucheryavyi
N.A. Semashko Central Clinical Hospital Two, ОАО “RZhD”
T. Oganesyan
N.A. Semashko Central Clinical Hospital Two, ОАО “RZhD”
References
- Devereaux P., Scott Beattie W., Choi P. et al. How strong is the evidence for the use of perioperative b-blockers in non-cardiac surgery? Systematic review and metaanalysis of randomised controlled trials // BMJ. - 2005; 331: 313-321.
- Рылова A.K., Розанов A.B. Терапия бета-блокаторами в специальных группах пациентов, страдающих ХСН (обзор результатов анализа в подгруппах исследований CIBIS. //, COMET., Copernicus и MERIT HF) // Сердце. - 2003; 2: 193-196.
- Flather M., Shibata М., Coats A. et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) // Eur. Heart J. - 2005; 26: 215-225.
- Маколкин В.И. Роль бета-блокаторов в лечении стабильной стенокардии // Трудный пациент, - 2006; 1: 5-10.
- Маколкин В.И. Позиция β-адреноблокаторов и диуретиков в обновленных Европейских рекомендациях по артериальной гипертензии (2009) // Лечащий врач. - 2010; 7: 35-39.
- Маколкин В.И. Выбор бета-блокаторов при артериальной гипертонии в сочетании с сахарным диабетом: принцип разумной целесообразности // Мат. научно-практической конф. «Метаболические аспекты артериальной гипертонии». Москва, 5 декабря 2002 г.
- Le Brocq М., Leslie S., Milliken P. et al. Endothelial dysfunction: from molecular mechanism stomeasurement, clinical implications, and therapeutic opportunities // Antioxid. Redox Signal. - 2008; 10: 1631-1674.
- Pedersen M., Cockcroft J. The vasodilatory beta-blockers // Curr. Hypertens. Rep. - 2007; 9: 269-277.
- Arosio E., De Marchi S., Prior M. et al. Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress // J. Hypertens. - 2002; 20: 1793-1797.
- Eagle K., Berger P., Calkins H. et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary // J. Am. Coll. Cardiol. - 2002; 39: 542-553.
- Cleophas T., Agrawal R., Lichtenthal A. et al. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients // Am. J. Ther. 2006; 13: 192-197.
- Cleophas T., Agrawal R., Lichtenthal A. et al. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients // Am. J. Ther. - 2006; 13: 192-197.
- Van Bortel L., Fici F., Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis // Am. J. Cardiovasc - Drugs. - 2008; 8: 35-44.
- Смирнова O.B. Сравнительная фармакотерапевтическая эффективность β-блокаторов различных групп (пропранолол, атенолол, небиволол) при хронической сердечной недостаточности в эксперименте и клинике: дисс.. канд. мед. наук, -ЯГМА., 2002. - С. 117.
- Dahlof В., Lindholm L. et al. Morbidity and mortality in the Swedish Trial in old patients with hypertension (STOP-Hypertension) // Lancet. - 1991; 338: 1281-1285.
- Medical Research Council Working Party. MRC Trial of treatment of mild hyperten-sion // BMJ. - 1985; 291: 47-104.
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and LipidLowering treatment to prevent Heart Attack Trial (ALLHAT) // JAMA. - 2002; 288: 2988-2997.